Literature DB >> 26364590

Practical guide for calculating and representing biased signaling by GPCR ligands: A stepwise approach.

Karim Nagi1, Graciela Pineyro2.   

Abstract

Signaling bias makes reference to the capacity of G-protein coupled receptor (GPCR) ligands to direct pharmacological stimuli to a subset of effectors among all of those controlled by the receptor. This new signaling modality has added texture to the classical notion of efficacy. In doing so, it has opened new avenues for the development of therapeutic GPCR ligands that specifically modulate signals underlying desired effects while sparing those that support undesired drug actions. Essential to taking advantage of this texture is the ability to identify, quantify and represent bias in a reliable and intuitive manner that ensures comparison among ligands. Here, we present a practical guide on how the operational model may be used to evaluate ligand efficiency to induce different responses, how differences in response may be used to estimate bias and how quantitative information derived from this analysis may be graphically represented to recreate a drug's unique signaling footprint. The approach used is discussed in terms of data interpretation and limitations that may influence the conclusions drawn from the analysis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bias; Drug development; Efficacy; Functional selectivity; Quantification; Texture

Mesh:

Substances:

Year:  2015        PMID: 26364590     DOI: 10.1016/j.ymeth.2015.09.010

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  7 in total

Review 1.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

2.  In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Authors:  Federica Ferrari; Maria Camilla Cerlesi; Davide Malfacini; Laila Asth; Elaine C Gavioli; Blair V Journigan; Uma Gayathri Kamakolanu; Michael E Meyer; Dennis Yasuda; Willma E Polgar; Anna Rizzi; Remo Guerrini; Chiara Ruzza; Nurulain T Zaveri; Girolamo Calo
Journal:  Eur J Pharmacol       Date:  2016-10-22       Impact factor: 4.432

Review 3.  The expanding repertoire of receptor activity modifying protein (RAMP) function.

Authors:  Klara R Klein; Brooke C Matson; Kathleen M Caron
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-01-06       Impact factor: 8.250

4.  Biased signaling by endogenous opioid peptides.

Authors:  Ivone Gomes; Salvador Sierra; Lindsay Lueptow; Achla Gupta; Shawn Gouty; Elyssa B Margolis; Brian M Cox; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-11       Impact factor: 11.205

5.  In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.

Authors:  Federica Ferrari; Davide Malfacini; Blair V Journigan; Mark F Bird; Claudio Trapella; Remo Guerrini; David G Lambert; Girolamo Calo'; Nurulain T Zaveri
Journal:  Pharmacol Res Perspect       Date:  2017-08

6.  Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH2.

Authors:  Salvatore Pacifico; Federica Ferrari; Valentina Albanese; Erika Marzola; Joaquim Azevedo Neto; Chiara Ruzza; Girolamo Calò; Delia Preti; Remo Guerrini
Journal:  J Med Chem       Date:  2020-09-24       Impact factor: 7.446

7.  A Dynamic Mass Redistribution Assay for the Human Sweet Taste Receptor Uncovers G-Protein Dependent Biased Ligands.

Authors:  Nicole B Servant; Mark E Williams; Paul F Brust; Huixian Tang; Melissa S Wong; Qing Chen; Marketa Lebl-Rinnova; Sara L Adamski-Werner; Catherine Tachdjian; Guy Servant
Journal:  Front Pharmacol       Date:  2022-02-17       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.